Kalexo Bio Overview
- Year Founded
-
2023
- Status
-
Private
- Latest Deal Type
-
Early Stage VC
- Investors
-
2
Kalexo Bio General Information
Description
Developer of siRNA therapeutics designed to target the genetic drivers of cardiovascular disease. The company's platform utilizes a dual-targeting approach to simultaneously silence multiple risk factors in a single regimen, enabling patients with dyslipidemia to achieve durable lipid management and prevent atherosclerotic cardiovascular disease events.
Contact Information
Website
www.kalexobio.comCorporate Office
- 1111 Broadway
- Suite 1300
- Oakland, CA 94607
- United States
Corporate Office
- 1111 Broadway
- Suite 1300
- Oakland, CA 94607
- United States
Kalexo Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC | 17-Sep-2025 | Completed | Pre-Clinical Trials |
Kalexo Bio Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Aditum Bio | Venture Capital | Minority | ||
| Mabwell | Corporation | Minority |
Kalexo Bio FAQs
-
When was Kalexo Bio founded?
Kalexo Bio was founded in 2023.
-
Where is Kalexo Bio headquartered?
Kalexo Bio is headquartered in Oakland, CA.
-
What industry is Kalexo Bio in?
Kalexo Bio’s primary industry is Drug Discovery.
-
Is Kalexo Bio a private or public company?
Kalexo Bio is a Private company.
-
What is Kalexo Bio’s current revenue?
The current revenue for Kalexo Bio is .
-
Who are Kalexo Bio’s investors?
Aditum Bio and Mabwell have invested in Kalexo Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process